Study at Sheppard Pratt links cognitive decline to mortality risk in schizophrenia

A recent study published in JAMA Network Open highlights the link between cognitive functioning and mortality risk in individuals with schizophrenia. Conducted at Sheppard Pratt, the research involved 844 participants diagnosed with schizophrenia or schizoaffective disorder, who were monitored for up to 24 years. The study utilized data from the National Death Index to track mortality causes, revealing that lower cognitive functioning significantly correlates with earlier natural cause mortality, including cardiac disease and cancer. Led by Dr. Faith Dickerson, the study emphasizes the importance of cognitive health in this vulnerable population. It found that individuals scoring in the lowest half on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) faced a heightened risk of premature death. Other contributing factors included elevated body mass index, tobacco use, and marital status, among others. The findings underscore the urgent need for targeted interventions aimed at improving cognitive functioning among those with schizophrenia. Dr. Dickerson advocates for a focus on enhancing cognitive abilities as a potential means to extend life expectancy and improve overall health outcomes for these individuals. This research not only contributes to the understanding of schizophrenia's impact on cognitive and physical health but also aims to inform clinical practices and treatment strategies. The study was co-authored by Dr. Robert Yolken and funded by The Stanley Medical Research Institute and Boehringer Ingelheim, reflecting a commitment to advancing mental health care through evidence-based research.